Endothelin antagonists for diabetic and non-diabetic chronic kidney disease

British Journal of Clinical Pharmacology

Volumn 76, Issue 4, 2013, Pages 573-579

  Kohan, Donald E ^a   Pollock, David M ^b  

^a UNIVERSITY OF UTAH HEALTH SCIENCES CENTER   (United States)

^b MEDICAL COLLEGE OF GEORGIA   (United States)

Author keywords

Antagonist; Chronic kidney disease; Diabetes; Endothelin; Receptor

Indexed keywords

AMBRISENTAN; ATRASENTAN; AVOSENTAN; BOSENTAN; CYCLO(DEXTRO TRYPTOPHYL DEXTRO ASPARTYLPROLYL DEXTRO VALYLLEUCYL); DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENDOTHELIN; ENDOTHELIN A RECEPTOR; ENDOTHELIN RECEPTOR ANTAGONIST; N (2,6 DIMETHYLPIPERIDINOCARBONYL) 4 METHYLLEUCYL DEXTRO (1 METHOXYCARBONYLTRYPTOPHANYL) DEXTRO NORLEUCINE; SITAXSENTAN; SULFONAMIDE; TAK 044;

ABSENCE OF SIDE EFFECTS; ALBUMINURIA; ANTIHYPERTENSIVE ACTIVITY; ARTICLE; CHRONIC KIDNEY DISEASE; CONGESTIVE HEART FAILURE; DIABETES MELLITUS; DIABETIC NEPHROPATHY; DOSE RESPONSE; DRUG MEGADOSE; DRUG SAFETY; ENZYME INHIBITION; FLUID RETENTION; FOCAL GLOMERULOSCLEROSIS; GLOMERULUS FILTRATION; HEMODIALYSIS PATIENT; HUMAN; HYPERTENSION; KIDNEY FAILURE; KIDNEY FUNCTION; KIDNEY INJURY; KIDNEY POLYCYSTIC DISEASE; LIVER TOXICITY; MORBIDITY; MORTALITY; NONHUMAN; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; PROTEINURIA; PULMONARY HYPERTENSION; RECEPTOR BLOCKING; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; SIDE EFFECT; TESTIS DISEASE; VASCULARIZATION; VASOCONSTRICTION;

ANTAGONIST; CHRONIC KIDNEY DISEASE; DIABETES; ENDOTHELIN; RECEPTOR;

ANIMALS; CLINICAL TRIALS AS TOPIC; DIABETIC NEPHROPATHIES; DOSE-RESPONSE RELATIONSHIP, DRUG; ENDOTHELIN-1; HUMANS; ISOXAZOLES; KIDNEY FAILURE, CHRONIC; PYRIDINES; PYRIMIDINES; RECEPTOR, ENDOTHELIN A; RECEPTOR, ENDOTHELIN B; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; THIOPHENES; TREATMENT OUTCOME;

EID: 84881152296     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/bcp.12064     Document Type: Article

References (65)

1. Kohan DE, Rossi NF, Inscho EW, Pollock DM. Regulation of blood pressure and salt homeostasis by endothelin. Physiol Rev 2011; 91: 1-77.
2. Kohan DE, Pritchett Y, Molitch M, Wen S, Garimella T, Audhya P, Andress DL. Addition of atrasentan to renin-angiotensin system blockade reduces albuminuria in diabetic nephropathy. J Am Soc Nephrol 2011; 22: 763-772.
3. Pollock DM, Pollock JS. Evidence for endothelin involvement in the response to high salt. Am J Physiol 2001; 281: F144-150.
4. Nambi P, Pullen M, Wu H, Aiyar N, Ohlstein EH, Edwards RM. Identification of endothelin receptor subtypes in human renal cortex and medulla using subtypes-selective ligands. Endocrinology 1992; 131: 1081-1086.
5. Kittikulsuth W, Pollock JS, Pollock DM. Loss of renal medullary endothelin B receptor function during salt deprivation is regulated by angiotensin II. Am J Physiol 2012; 303: F659-666.
6. Speed JS, LaMarca B, Berry H, Cockrell K, George EM, Granger JP. Renal medullary endothelin-1 is decreased in Dahl salt-sensitive rats. Am J Physiol 2011; 301: R519-523.
7. Boesen EI, Krishnan KR, Pollock JS, Pollock DM. ETA activation mediates angiotensin II-induced infiltration of renal cortical T cells. J Am Soc Nephrol 2011; 22: 2187-2192.
8. Saleh MA, Boesen EI, Pollock JS, Savin VJ, Pollock DM. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010; 56: 942-949.
9. Kittikulsuth W, Pollock JS, Pollock DM. Sex differences in renal medullary endothelin receptor function in angiotensin II hypertensive rats. Hypertension 2011; 58: 212-218.
10. Benigni A, Perico N, Remuzzi G. Endothelin antagonists and renal protection. J Cardiovasc Pharmacol 2000; 35: S75-78.
11. Remuzzi G, Perico N, Benigni A. New therapeutics that antagonize endothelin: promises and frustrations. Nat Rev Drug Discov 2002; 1: 986-1001.
12. Loomis ED, Sullivan JC, Osmond DA, Pollock DM, Pollock JS. Endothelin mediates superoxide production and vasoconstriction through activation of NADPH oxidase and uncoupled nitric-oxide synthase in the rat aorta. J Pharmacol Exp Ther 2005; 315: 1058-1064.
13. Sasser JM, Sullivan JC, Hobbs JL, Yamamoto T, Pollock DM, Carmines PK, Pollock JS. Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism. J Am Soc Nephrol 2007; 18: 143-154.
14. Rebibou JM, He CJ, Delarue F, Peraldi MN, Adida C, Rondeau E, Sraer JD. Functional endothelin-1 receptors on human glomerular podocytes and mesangial cells. Nephrol Dial Transplant 1992; 7: 288-292.
15. Hocher B, Schwarz A, Reinbacher D, Jacobi J, Lun A, Priem F, Bauer C, Neumayer HH, Raschack M. Effects of endothelin receptor antagonists on the progression of diabetic nephropathy. Nephron 2001; 87: 161-169.
16. Saleh MA, Pollock JS, Pollock DM. Distinct actions of endothelin A-selective versus combined endothelin A/B receptor antagonists in early diabetic kidney disease. J Pharmacol Exp Ther 2011; 338: 263-270.
17. Sugimoto H, Shikata K, Hirata K, Akiyama K, Matsuda M, Kushiro M, Shikata Y, Miyatake N, Miyasaka M, Makino H. Increased expression of intercellular adhesion molecule-1 (ICAM-1) in diabetic rat glomeruli: glomerular hyperfiltration is a potential mechanism of ICAM-1 upregulation. Diabetes 1997; 46: 2075-2081.
18. Gagliardini E, Corna D, Zoja C, Sangalli F, Carrara F, Rossi M, Conti S, Rottoli D, Longaretti L, Remuzzi A, Remuzzi G, Benigni A. Unlike each drug alone, lisinopril if combined with avosentan promotes regression of renal lesions in experimental diabetes. Am J Physiol 2009; 297: F1448-1456.
19. Watson AM, Li J, Schumacher C, de Gasparo M, Feng B, Thomas MC, Allen TJ, Cooper ME, Jandeleit-Dahm KA. The endothelin receptor antagonist avosentan ameliorates nephropathy and atherosclerosis in diabetic apolipoprotein E knockout mice. Diabetologia 2010; 53: 192-203.
20. Zoja C, Cattaneo S, Fiordaliso F, Lionetti V, Zambelli V, Salio M, Corna D, Pagani C, Rottoli D, Bisighini C, Remuzzi G, Benigni A. Distinct cardiac and renal effects of ETA receptor antagonist and ACE inhibitor in experimental type 2 diabetes. Am J Physiol 2011; 301: F1114-1123.
21. Hocher B, Lun A, Priem F, Neumayer H, Raschack M. Renal endothelin system in diabetes: comparison of angiotensin-converting enzyme inhibition and endothelin-A antagonism. J Cardiovasc Pharmacol 1998; 31: (Suppl. 1): S492-495.
22. Ding SS, Qiu C, Hess P, Xi JF, Zheng N, Clozel M. Chronic endothelin receptor blockade prevents both early hyperfiltration and late overt diabetic nephropathy in the rat. J Cardiovasc Pharmacol 2003; 42: 48-54.
23. Saleh MA, Sandoval RM, Rhodes GJ, Campos-Bilderback SB, Molitoris BA, Pollock DM. Chronic endothelin-1 infusion elevates glomerular sieving coefficient and proximal tubular albumin reuptake in the rat. Life Sci 2012; 91: 634-637.
24. Yang B, Li M, Shi ZG, Feng QZ. Bosentan ameliorates the expression of fibrotic related growth factors and collagen-1 in diabetic mice. Anadolu Kardiyol Derg 2012; 12: 621-627 (Epub ahead of print).
25. Chang MY, Parker E, El Nahas M, Haylor JL, Ong AC. Endothelin B receptor blockade accelerates disease progression in a murine model of autosomal dominant polycystic kidney disease. J Am Soc Nephrol 2007; 18: 560-569.
26. Forbes J, Hewitson T, Becker G, Jones C. Simultaneous blockade of endothelin A and B receptors in ischemic acute renal failure is detrimental to long-term kidney function. Kidney Int 2001; 59: 1333-1341.
27. Grenda R, Wuhl E, Litwin M, Janas R, Sladowska J, Arbeiter K, Berg U, Caldas-Afonso A, Fischbach M, Mehls O, Sallay P, Schaefer F. Urinary excretion of endothelin-1 (ET-1), transforming growth factor- beta1 (TGF- beta1) and vascular endothelial growth factor (VEGF165) in paediatric chronic kidney diseases: results of the ESCAPE trial. Nephrol Dial Transplant 2007; 22: 3487-3494.
28. Kohan D. Endothelins in the normal and diseased kidney. Am J Kidney Dis 1997; 29: 2-26.
29. Mallamaci F, Parlongo S, Zoccali C. Influence of cardiovascular damage and residual renal function on plasma endothelin in chronic renal failure. Nephron 1993; 63: 291-295.
30. Zanatta CM, Gerchman F, Burttet L, Nabinger G, Jacques-Silva MC, Canani LH, Gross JL. Endothelin-1 levels and albuminuria in patients with type 2 diabetes mellitus. Diabetes Res Clin Pract 2008; 80: 299-304.
31. Phisitkul S, Khanna A, Simoni J, Broglio K, Sheather S, Rajab MH, Wesson DE. Amelioration of metabolic acidosis in patients with low GFR reduced kidney endothelin production and kidney injury, and better preserved GFR. Kidney Int 2010; 77: 617-623.
32. Mahajan A, Simoni J, Sheather SJ, Broglio KR, Rajab MH, Wesson DE. Daily oral sodium bicarbonate preserves glomerular filtration rate by slowing its decline in early hypertensive nephropathy. Kidney Int 2010; 78: 303-309.
33. Lilitkarntakul P, Dhaun N, Melville V, Blackwell S, Talwar DK, Liebman B, Asai T, Pollock J, Goddard J, Webb DJ. Blood pressure and not uraemia is the major determinant of arterial stiffness and endothelial dysfunction in patients with chronic kidney disease and minimal co-morbidity. Atherosclerosis 2011; 216: 217-225.
34. Goddard J, Johnston NR, Hand MF, Cumming AD, Rabelink TJ, Rankin AJ, Webb DJ. Endothelin-A receptor antagonism reduces blood pressure and increases renal blood flow in hypertensive patients with chronic renal failure: a comparison of selective and combined endothelin receptor blockade. Circulation 2004; 109: 1186-1193.
35. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Blood pressure-independent reduction in proteinuria and arterial stiffness after acute endothelin-a receptor antagonism in chronic kidney disease. Hypertension 2009; 54: 113-119.
36. Dhaun N, Macintyre IM, Melville V, Lilitkarntakul P, Johnston NR, Goddard J, Webb DJ. Effects of endothelin receptor antagonism relate to the degree of renin-angiotensin system blockade in chronic proteinuric kidney disease. Hypertension 2009; 54: e19-20.
37. Dhaun N, Ferro CJ, Davenport AP, Haynes WG, Goddard J, Webb DJ. Haemodynamic and renal effects of endothelin receptor antagonism in patients with chronic kidney disease. Nephrol Dial Transplant 2007; 22: 3228-3234.
38. Neuhofer W, Pittrow D. Endothelin receptor selectivity in chronic kidney disease: rationale and review of recent evidence. Eur J Clin Invest 2009; 39: (Suppl. 2): 50-67.
39. Wenzel RR, Littke T, Kuranoff S, Jurgens C, Bruck H, Ritz E, Philipp T, Mitchell A. Avosentan reduces albumin excretion in diabetics with macroalbuminuria. J Am Soc Nephrol 2009; 20: 655-664.
40. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G. Avosentan for overt diabetic nephropathy. J Am Soc Nephrol 2010; 21: 527-535.
41. Dhaun N, MacIntyre IM, Kerr D, Melville V, Johnston NR, Haughie S, Goddard J, Webb DJ. Selective endothelin-A receptor antagonism reduces proteinuria, blood pressure, and arterial stiffness in chronic proteinuric kidney disease. Hypertension 2011; 57: 772-779.
42. Evaluate the efficacy and safety of once daily administration of atrasentan tablets (low and high) compared to placebo in reducing residual albuminuria in type 2 diabetic patients with nephropathy who are treated with the maximum tolerated labeled dose of a renin angiotensin system (RAS) inhibitor (RADAR). 2011. Available at http://clinicaltrials.gov/ct2/show/NCT01356849?term=endothelin+atrasentan+radar&rank=1 (last accessed 26 December 2012).
43. Reducing residual albuminuria in subjects with diabetes and nephropathy with atrasentan. 2011. Available at http://clinicaltrials.gov/ct2/show/NCT01424319?term=endothelin+atrasentan+residual&rank=1 (last accessed 26 December 2012).
44. A prospective, double-blind, placebo-controlled, multicenter study to evaluate efficacy and safety of atrasentan, including thoracic bioimpedance, in type 2 diabetic subjects with nephropathy. 2011. Available at http://clinicaltrials.gov/ct2/show/NCT01399580?term=endothelin+atrasentan+bioimpedance&rank=1 (last accessed 26 December 2012).
45. A randomized, double-blind, study to explore the efficacy and safety of RE-021 in focal segmental glomerulosclerosis (FONT-3). 2012. Available at http://clinicaltrials.gov/ct2/show/NCT01613118?term=endothelin+font-3&rank=1 (last accessed 26 December 2012).
46. Effect of bosentan in scleroderma renal crisis (ScS-REINBO). 2010. Available at http://clinicaltrials.gov/ct2/show/NCT01241383?term=endothelin+bosentan+scleroderma&rank=2 (last accessed 26 December 2012).
47. Penn H, Burns A, Black C, Denton C. An open label trial of the endothelin receptor antagonist bosentan in scleroderma renal crisis (BIRD-1). Arthritis Rheum 2009; 60: (Suppl. 10): 451. (abstract).
48. Ebihara I, Nakamura T, Takahashi T, Tomino Y, Shimada N, Koide H. Increased endothelin-1 mRNA expression in peripheral blood monocytes of dialysis patients. Perit Dial Int 1997; 17: 595-601.
49. Lebel M, Grose JH, Kingma I, Langlois S. Plasma endothelin levels and blood pressure in hemodialysis and in CAPD patients. Effect of subcutaneous erythropoietin replacement therapy. Clin Exp Hypertens 1994; 16: 565-575.
50. Tomic M, Galesic K, Markota I. Endothelin-1 and nitric oxide in patients on chronic hemodialysis. Ren Fail 2008; 30: 836-842.
51. Vlachojannis J, Tsakas S, Chinari E, Orphanos V, Zoumbos N, Kurz P. Increased endothelin-1 content in the platelets of hemodialysed patients. Clin Nephrol 1997; 48: 185-190.
52. Erkan E, Devarajan P, Kaskel F. Role of nitric oxide, endothelin-1, and inflammatory cytokines in blood pressure regulation in hemodialysis patients. Am J Kidney Dis 2002; 40: 76-81.
53. Ottosson-Seeberger A, Ahlborg G, Hemsen A, Lundberg JM, Alvestrand A. Hemodynamic effects of endothelin-1 and big endothelin-1 in chronic hemodialysis patients. J Am Soc Nephrol 1999; 10: 1037-1044.
54. Kanbay M, Akcay A, Delibasi T, Uz B, Kaya A, Koca C, Turgut F, Bavbek N, Uz E, Duranay M, Yigitoglu R. Comparison of effects of darbepoetin alfa and epoetin alfa on serum endothelin level and blood pressure. Adv Ther 2007; 24: 346-352.
55. Wilkie ME, Khandan-Nia N, Ghatei MA, Bloom SR, Raftery MJ, Cunningham J. Does the arteriovenous fistula in chronic haemodialysis patients stimulate endothelin-1 release? Nephrol Dial Transplant 1992; 7: 1019-1021.
56. Karakitsos D, Patrianakos AP, Parthenakis FI, Malliaraki N, Nikitovic D, Kyriazis J, Karabinis A, Groothoff JW, de Groot E, Fourtounas C, Daphnis E, Vardas PE. Altered proximal aortic stiffness and endothelin plasma levels in diabetic patients with end-stage renal disease. ASAIO J 2007; 53: 343-350.
57. Liu H, Peng Y, Liu F, Liu Y, Ouyang L, Xiao W, Cheng M, Chen X, Gao L. Correlation between endothelin-1 and atherosclerosis in chronic hemodialysis patients. J Nephrol 2010; 23: 593-602.
58. Noshad H, Argani H, Nezami N, Ghojazadeh M, Zomorrodi A, Bohlouli A, Bonyadi MR, Fakhrjou A, Ghorbanihaghjo A, Gharedaghi A, Javadzadegan H, Sadreddini S. Arterial atherosclerosis in patients with chronic kidney disease and its relationship with serum and tissue endothelin-1. [corrected]. Iran J Kidney Dis 2009; 3: 203-209.
59. Rabkin SW. Endothelin but not angiotensin II may mediate hypertension-induced coronary vascular calcification in chronic kidney disease. Int J Nephrol 2011; 2011: 1-7.
60. Dao HH, Essalihi R, Graillon JF, Lariviere R, De Champlain J, Moreau P. Pharmacological prevention and regression of arterial remodeling in a rat model of isolated systolic hypertension. J Hypertens 2002; 20: 1597-1606.
61. Abassi Z, Nakhoul F, Khankin E, Reisner SA, Yigla M. Pulmonary hypertension in chronic dialysis patients with arteriovenous fistula: pathogenesis and therapeutic prospective. Curr Opin Nephrol Hypertens 2006; 15: 353-360.
62. Liefeldt L, van Giersbergen PL, Dingemanse J, Rudolph B, Walde T, Budde K, Neumayer HH, Hocher B. Treatment of secondary pulmonary hypertension with bosentan and its pharmacokinetic monitoring in ESRD. Am J Kidney Dis 2004; 43: 923-926.
63. Kohan DE, Cleland JG, Rubin LJ, Theodorescu D, Barton M. Clinical trials with endothelin receptor antagonists: what went wrong and where can we improve? Life Sci 2012; 91: 528-539.
64. Safdar Z. Effect of transition from sitaxsentan to ambrisentan in pulmonary arterial hypertension. Vasc Health Risk Manag 2011; 7: 119-124.
65. Barton M, Kohan DE. Endothelin antagonists in clinical trials: lessons learned. Contrib Nephrol 2011; 172: 255-260.